Funding to Help the Bridge Science

07.22.14 | By

Pharmacology is often described as a bridge science because it incorporates knowledge and skills from a number of basic science disciplines including physiology, biochemistry and cell and molecular biology. Pharmacologists are able to 'translate' such knowledge into the rational development of therapeutics. As a result of their multidisciplinary training, pharmacologists are able to offer a unique perspective in solving drug-, hormone- and chemical-related problems.

New Cancer Medicines Driving Value for Patients

07.22.14 | By

If conventional wisdom says that spending on new cancer medicines is at “unsustainable” levels, and a demonstration project designed to address this leads to increased spending on new cancer medicines and reduced total medical costs, then what happens to conventional wisdom? That’s one question you might be left with after reading the surprising results of the much-anticipated study by Lee Newcomer, MD from United Healthcare and two cancer centers. The study was designed to cut cancer treatment costs, and to do so by reducing use of new cancer medicines.

Debunking the Myths of Treating Hepatitis C

07.21.14 | By

A national dialogue is needed around the value of new medicines and cures and the role they play in improving patient health and helping to manage long-term spending in the U.S. health care system.   Unfortunately, the debate around hepatitis C has, for the most part, been twisted to the point that modern-day cures are seen as a nuisance rather than a monumental step forward in the battle against disease.  For this reason, it is important to set the record straight on some of the misperceptions about the value of new and forthcoming hepatitis C treatments.

Week in Review: The Fight for Innovation and Access

07.18.14 | By

Our president and CEO John Castellani asked, “What would happen if the pace of medical innovation in the U.S. slowed or halted altogether?” It’s a scary thought when you consider that without research and development (R&D), the treatments patients have come to depend on and hope to see in the future would not and will not exist. As a result, this week we highlighted a few extraordinary advancements and discussed what it means when patients do not have access to necessary treatments.

Burden on Patients: Looking Ahead

07.17.14 | By

Without access to essential health care treatments and services, having health insurance coverage is pointless. Being covered should equate to high-quality, affordable health care, but this is not the case for many individuals in the Affordable Care Act (ACA) health insurance exchanges.

What They Are Saying about New Hep C Cure: “That's actually a great deal”

07.17.14 | By

Vox’s Sarah Kliff talked to some health economists about the new cure for hepatitis C that has gotten so much attention in recent weeks.  What she heard may surprise you.  Check out her article here: Each of these Hepatitis C pills cost $1,000. That's actually a great deal.

Here are a few highlights:

A Visual Journey: How HIV/AIDS Became a Treatable Disease

07.17.14 | By

When doctors first began reporting HIV/AIDS cases in the early 1980s there were few effective options that could help combat or manage the deadly disease. As a result, the condition was quickly dubbed a near-certain death sentence.

Forbes Contributor Prescribes Important Changes to Improve Information Sharing in Our Healthcare System

07.16.14 | By

Continuing an important conversation about how to make the best use of the wealth of information regarding today’s healthcare treatment options, last week Nicole Fisher wrote in Forbes about the growing need for a new regulatory paradigm to govern how the biopharmaceutical industry communicates with healthcare professionals about medicines.

340B: Keeping a Promise to Patients

07.16.14 | By

The 340B program was created to help vulnerable and uninsured patients access needed medicines. However, the program continues to grow exponentially without appropriate guardrails, putting it at risk. Appropriate oversight and reform is needed to ensure the 340B program can fulfill its promise to patients.

The Voices of Schizophrenia and the Potential in the Pipeline

07.15.14 | By

Around 2.4 million American adults have schizophrenia each year and onset can be caused by a combination of genetic predisposition and external stressors. Learn more about the 119 medicines in development for mental health.


Subscribe to RSS - Opinion